Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)
Clinical trial NCT05323435 · COMPLETED
Trial details
- NCT number
- NCT05323435
- Sponsor
- Jiangsu Rec-Biotechnology Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-30
- Primary completion
- 2022-07-05
- Enrollment
- 300
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.